As Sarepta And Valeant Exit Hearings, Biotech Steps Into M&A

The last week was a nonstop whirlwind for biotech, so I've decided to treat this entry a little differently by commenting on key events and sharing what I've been seeing. Valeant's outgoing CEO J. Michael Pearson,former chief financial officer Howard Schiller and billionaire investor William Ackman, whose hedge fund holds a [...]